Holen Sie sich die Stockscreener-App
3.99
1.36%
-0.05
Schlusskurs vom Vortag:
$4.04
Offen:
$4.03
24-Stunden-Volumen:
104.67K
Relative Volume:
0.03
Marktkapitalisierung:
$89.80M
Einnahmen:
$32.77M
Nettoeinkommen (Verlust:
$-101.98M
KGV:
-0.4152
EPS:
-9.6101
Netto-Cashflow:
$-112.43M
1W Leistung:
+6.55%
1M Leistung:
+14.51%
6M Leistung:
+6.98%
1J Leistung:
-74.41%
1-Tages-Spanne:
$3.95
$4.03
1-Wochen-Bereich:
$3.67
$4.11
52-Wochen-Spanne:
$1.35
$26.83
X 4 Pharmaceuticals Inc Stock (XFOR) Company Profile
Firmenname
X 4 Pharmaceuticals Inc
Sektor
Branche
Telefon
857-529-8300
Adresse
61 NORTH BEACON STREET, BOSTON, MA
Vergleichen Sie XFOR mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
XFOR
X 4 Pharmaceuticals Inc
|
4.00 | 320.03M | 32.77M | -101.98M | -112.43M | -9.6101 |
|
VRTX
Vertex Pharmaceuticals Inc
|
421.33 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
633.37 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
434.56 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
817.41 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
181.50 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
X 4 Pharmaceuticals Inc Stock (XFOR) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2023-12-12 | Herabstufung | B. Riley Securities | Buy → Neutral |
| 2023-08-30 | Fortgesetzt | B. Riley Securities | Buy |
| 2022-12-22 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2022-12-12 | Eingeleitet | Piper Sandler | Overweight |
| 2019-12-23 | Eingeleitet | Oppenheimer | Outperform |
| 2019-12-18 | Eingeleitet | ROTH Capital | Buy |
| 2019-12-09 | Hochstufung | Citigroup | Neutral → Buy |
| 2019-12-05 | Eingeleitet | B. Riley FBR | Buy |
| 2019-06-07 | Eingeleitet | Stifel | Buy |
| 2019-06-05 | Eingeleitet | Cowen | Outperform |
Alle ansehen
X 4 Pharmaceuticals Inc Aktie (XFOR) Neueste Nachrichten
How strong is X4 Pharmaceuticals Inc. stock revenue growthInflation Watch & Expert Approved Trade Ideas - newser.com
How to build a dashboard for X4 Pharmaceuticals Inc. stock2025 AllTime Highs & Low Drawdown Investment Strategies - newser.com
Top chart patterns to watch in X4 Pharmaceuticals Inc.July 2025 Market Mood & Reliable Entry Point Alerts - newser.com
Using economic indicators to assess X4 Pharmaceuticals Inc. potentialTrade Volume Report & Safe Entry Zone Identification - newser.com
Why X4 Pharmaceuticals Inc. stock could benefit from AI revolutionWeekly Market Summary & Reliable Intraday Trade Alerts - newser.com
Is X4 Pharmaceuticals Inc. (48Q0) stock a fit for income portfoliosDollar Strength & Free Reliable Trade Execution Plans - newser.com
What moving averages say about X4 Pharmaceuticals Inc.Earnings Growth Summary & Weekly Chart Analysis and Guides - newser.com
Will X4 Pharmaceuticals Inc. stock benefit from commodity pricesDay Trade & Capital Efficiency Focused Strategies - newser.com
Will X4 Pharmaceuticals Inc. stock recover after recent dropPrice Action & Advanced Swing Trade Entry Plans - newser.com
What recovery options are there for X4 Pharmaceuticals Inc.Quarterly Earnings Summary & Community Supported Trade Ideas - newser.com
Will X4 Pharmaceuticals Inc. stock benefit from AI adoptionMarket Performance Summary & AI Forecasted Entry and Exit Points - newser.com
Combining machine learning predictions for X4 Pharmaceuticals Inc.July 2025 Trends & Precise Trade Entry Recommendations - newser.com
Can volume confirm reversal in X4 Pharmaceuticals Inc.Trade Signal Summary & AI Forecasted Entry/Exit Points - newser.com
How dovish Fed policy supports X4 Pharmaceuticals Inc. (48Q0) stockPortfolio Profit Report & Technical Entry and Exit Alerts - newser.com
X4 Pharmaceuticals Inc 48Q0 Stock Analysis and ForecastTechnical Breakout Signals & Double Digit Wealth Tips - earlytimes.in
Published on: 2025-10-28 05:23:25 - newser.com
X4 Pharmaceuticals Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $155.3 Million - The Manila Times
X4 Pharmaceuticals Completes $155.3 Million Public Offering of Common Stock - Quiver Quantitative
X4 Pharma (NASDAQ: XFOR) closes $155.3M offering; underwriters' option fully exercised - Stock Titan
Craig Adam R buys x4 pharmaceuticals shares for $249,997 - Investing.com India
Why X4 Pharmaceuticals Inc. stock appeals to dividend seekers2025 Technical Overview & Consistent Profit Alerts - fcp.pa.gov.br
Why X4 Pharmaceuticals Inc. stock is a value investor pickJuly 2025 Gainers & Long Hold Capital Preservation Plans - Fundação Cultural do Pará
X4 Pharmaceuticals announces $145.6 million public offering of common stock - Investing.com
What candlestick patterns are forming on X4 Pharmaceuticals Inc.Earnings Overview Summary & Short-Term Swing Trade Alerts - newser.com
X4 Pharmaceuticals Bolsters Financial Stability Amid Strategic Development - StocksToTrade
X4 Pharmaceuticals Eyes Future Growth with $135 Million Offering - StocksToTrade
X4 Pharmaceuticals’ Public Offering Spurs Market Interest - timothysykes.com
X4 Pharmaceuticals (NASDAQ:XFOR) Upgraded at Zacks Research - Defense World
X4 Pharmaceuticals announces pricing of $135 million underwritten public offering at $2.90 per share - MarketScreener
X4 Pharmaceuticals Announces Pricing of $135 Million Underwritten Public Offering - MarketScreener
X4 Pharmaceuticals (NASDAQ: XFOR) prices $135M offering to fund Phase 3 mavorixafor - Stock Titan
X4 Pharmaceuticals announces proposed underwritten public offering - MarketScreener
X4 Pharmaceuticals (NASDAQ: XFOR) commences equity offering; 30-day 15% option - Stock Titan
X4 Pharmaceuticals (XFOR) Upgraded to Strong Buy: What Does It Mean for the Stock? - Yahoo Finance
Finanzdaten der X 4 Pharmaceuticals Inc-Aktie (XFOR)
Umsatz
Nettogewinn
Free Cashflow
ENV
X 4 Pharmaceuticals Inc-Aktie (XFOR) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Baldry Mark | Chief Commercial Officer |
May 16 '25 |
Buy |
2.48 |
1,032 |
2,561 |
25,337 |
| Baldry Mark | Chief Commercial Officer |
Nov 15 '24 |
Buy |
0.34 |
13,404 |
4,598 |
129,173 |
| Ragan Paula | President and CEO |
Jan 24 '25 |
Sale |
0.45 |
76,473 |
34,719 |
1,087,386 |
| Mostafa Adam S. | Chief Financial Officer |
Jan 24 '25 |
Sale |
0.45 |
74,773 |
33,947 |
0 |
| Baldry Mark | Chief Commercial Officer |
Jan 24 '25 |
Sale |
0.45 |
29,159 |
13,241 |
94,123 |
| DiBiase Mary | Chief Operating Officer |
Jan 24 '25 |
Sale |
0.45 |
22,258 |
10,094 |
490,980 |
| Arbet-Engels Christophe | Chief Medical Officer |
Jan 24 '25 |
Sale |
0.45 |
11,624 |
5,284 |
14,207 |
0.66%
0.84%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):